zonisamide has been researched along with Obesity in 16 studies
Zonisamide: A benzisoxazole and sulfonamide derivative that acts as a CALCIUM CHANNEL blocker. It is used primarily as an adjunctive antiepileptic agent for the treatment of PARTIAL SEIZURES, with or without secondary generalization.
zonisamide : A 1,2-benzoxazole compound having a sulfamoylmethyl substituent at the 3-position.
Obesity: A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).
| Excerpt | Relevance | Reference |
|---|---|---|
| "In this 10-week, double blind randomized placebo controlled clinical trial, forty one patients with schizophrenia diagnosed according to DSM-IV-TR criteria who were taking a stable dose of atypical antipsychotic are allocated into one of the two groups of zonisamide or placebo group." | 9.17 | The effect of zonisamide on antipsychotic-associated weight gain in patients with schizophrenia: a randomized, double-blind, placebo-controlled clinical trial. ( Ghanizadeh, A; Nikseresht, MS; Sahraian, A, 2013) |
| "Zonisamide at the daily dose of 400 mg moderately enhanced weight loss achieved with diet and lifestyle counseling but had a high incidence of adverse events." | 9.16 | Zonisamide for weight reduction in obese adults: a 1-year randomized controlled trial. ( Allison, DB; Bray, GA; Gadde, KM; Kopping, MF; Wagner, HR; Yonish, GM, 2012) |
| "Compared with placebo, zonisamide was associated with a significantly greater rate of reduction in binge eating episode frequency (p = ." | 9.12 | Zonisamide in the treatment of binge eating disorder with obesity: a randomized controlled trial. ( D'Alessio, DA; Guerdjikova, AI; Hudson, JI; Keck, PE; Kotwal, R; Lake, KA; McElroy, SL; Nelson, EB; Welge, JA, 2006) |
| "Zonisamide and bupropion have been investigated for weight reduction in obese adults." | 9.12 | Combination therapy of zonisamide and bupropion for weight reduction in obese women: a preliminary, randomized, open-label study. ( Foust, MS; Gadde, KM; Wagner, HR; Yonish, GM, 2007) |
| "In this short-term, preliminary trial, zonisamide and hypocaloric diet resulted in more weight loss than placebo and hypocaloric diet in the treatment of obesity." | 9.10 | Zonisamide for weight loss in obese adults: a randomized controlled trial. ( Franciscy, DM; Gadde, KM; Krishnan, KR; Wagner, HR, 2003) |
| " We performed an open-label, observational study to assess the effects of zonisamide on weight in overweight female epilepsy patients." | 7.78 | Low serum leptin level is associated with zonisamide-induced weight loss in overweight female epilepsy patients. ( Kim, DW; Park, KS; Yoo, MW, 2012) |
| "In this 10-week, double blind randomized placebo controlled clinical trial, forty one patients with schizophrenia diagnosed according to DSM-IV-TR criteria who were taking a stable dose of atypical antipsychotic are allocated into one of the two groups of zonisamide or placebo group." | 5.17 | The effect of zonisamide on antipsychotic-associated weight gain in patients with schizophrenia: a randomized, double-blind, placebo-controlled clinical trial. ( Ghanizadeh, A; Nikseresht, MS; Sahraian, A, 2013) |
| "Zonisamide at the daily dose of 400 mg moderately enhanced weight loss achieved with diet and lifestyle counseling but had a high incidence of adverse events." | 5.16 | Zonisamide for weight reduction in obese adults: a 1-year randomized controlled trial. ( Allison, DB; Bray, GA; Gadde, KM; Kopping, MF; Wagner, HR; Yonish, GM, 2012) |
| "Compared with placebo, zonisamide was associated with a significantly greater rate of reduction in binge eating episode frequency (p = ." | 5.12 | Zonisamide in the treatment of binge eating disorder with obesity: a randomized controlled trial. ( D'Alessio, DA; Guerdjikova, AI; Hudson, JI; Keck, PE; Kotwal, R; Lake, KA; McElroy, SL; Nelson, EB; Welge, JA, 2006) |
| "Zonisamide and bupropion have been investigated for weight reduction in obese adults." | 5.12 | Combination therapy of zonisamide and bupropion for weight reduction in obese women: a preliminary, randomized, open-label study. ( Foust, MS; Gadde, KM; Wagner, HR; Yonish, GM, 2007) |
| "In this short-term, preliminary trial, zonisamide and hypocaloric diet resulted in more weight loss than placebo and hypocaloric diet in the treatment of obesity." | 5.10 | Zonisamide for weight loss in obese adults: a randomized controlled trial. ( Franciscy, DM; Gadde, KM; Krishnan, KR; Wagner, HR, 2003) |
| "On the basis of six randomized controlled trials, zonisamide (ZNS) can be prescribed as add-on treatment in focal adulthood epilepsy in USA and Europe." | 4.85 | [Role of zonisamid in treating epilepsy, Parkinson disorders and other neurological diseases]. ( Janszky, J, 2009) |
| "The use of topiramate and zonisamide as lead molecules for the design of CA inhibitors targeting isozymes involved in lipogenesis could represent the beginning of a very promising new approach for the treatment of obesity." | 4.84 | Carbonic anhydrase inhibitors as emerging drugs for the treatment of obesity. ( De Simone, G; Di Fiore, A; Supuran, CT, 2008) |
| " We performed an open-label, observational study to assess the effects of zonisamide on weight in overweight female epilepsy patients." | 3.78 | Low serum leptin level is associated with zonisamide-induced weight loss in overweight female epilepsy patients. ( Kim, DW; Park, KS; Yoo, MW, 2012) |
| "Obesity is ranked as one of the top 10 global health problems and the major concern deriving from it is the exposure of the population to a vast array of chronic pathologies such as cardiovascular and musculoskeletal disorders, type 2 diabetes, cancer, such as colon, breast and endometrial cancer, together with psychological disorders derived from this condition." | 2.49 | Antiobesity carbonic anhydrase inhibitors: a literature and patent review. ( Carta, F; Scozzafava, A; Supuran, CT, 2013) |
| "Obesity is strongly associated with conditions such as hypertension, diabetes mellitus and osteoarthritis that have known adverse health outcomes." | 2.43 | Pharmacologic treatment of obesity. ( Cheskin, LJ; Sidhaye, A, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 8 (50.00) | 29.6817 |
| 2010's | 8 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ghanizadeh, A | 1 |
| Nikseresht, MS | 1 |
| Sahraian, A | 1 |
| Scozzafava, A | 1 |
| Supuran, CT | 2 |
| Carta, F | 1 |
| Shin, JH | 1 |
| Gadde, KM | 5 |
| Østbye, T | 1 |
| Bray, GA | 2 |
| Fujioka, K | 1 |
| Janszky, J | 2 |
| Horvath, R | 1 |
| Komoly, S | 1 |
| Di Fiore, A | 1 |
| De Simone, G | 1 |
| Kim, DW | 1 |
| Yoo, MW | 1 |
| Park, KS | 1 |
| Katz, MH | 1 |
| Kopping, MF | 1 |
| Wagner, HR | 3 |
| Yonish, GM | 2 |
| Allison, DB | 1 |
| Franciscy, DM | 1 |
| Krishnan, KR | 1 |
| Sidhaye, A | 1 |
| Cheskin, LJ | 1 |
| McElroy, SL | 1 |
| Kotwal, R | 1 |
| Guerdjikova, AI | 1 |
| Welge, JA | 1 |
| Nelson, EB | 1 |
| Lake, KA | 1 |
| D'Alessio, DA | 1 |
| Keck, PE | 1 |
| Hudson, JI | 1 |
| Foust, MS | 1 |
| Aylwin, S | 1 |
| Al-Zaman, Y | 1 |
| Wallingford, NM | 1 |
| Sinnayah, P | 1 |
| Bymaster, FP | 1 |
| Krishnan, RK | 1 |
| McKinney, AA | 1 |
| Landbloom, RP | 1 |
| Tollefson, GD | 1 |
| Cowley, MA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Zonisamide for Weight Reduction in Obese Adults[NCT00275834] | 225 participants (Actual) | Interventional | 2006-01-31 | Completed | |||
| Zonegran in the Treatment of Binge Eating Disorder Associated With Obesity: A Single Center, Double-Blind, Placebo-controlled, Flexible-Dose Study in Outpatients[NCT00221442] | Phase 3 | 60 participants (Actual) | Interventional | 2005-08-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The primary endpoint was weight loss at 1-year, Month-12 weight minus baseline weight, in kilograms. (NCT00275834)
Timeframe: 1 year
| Intervention | kg (Mean) |
|---|---|
| Placebo | -4.0 |
| Zonisamide 200 mg | -4.4 |
| Zonisamide 400 mg | -7.3 |
C reactive Protein (CRP) (NCT00275834)
Timeframe: 1 year
| Intervention | mg/L (Mean) |
|---|---|
| Placebo | 0.523 |
| Zonisamide 200 mg | 0.536 |
| Zonisamide 400 mg | 0.443 |
This outcomes measure followed the same principles at measurement of proportions of patients with 5% weight loss described elsewhere. (NCT00275834)
Timeframe: 1 year
| Intervention | participants (Number) |
|---|---|
| Placebo | 6 |
| Zonisamide 200 mg | 17 |
| Zonisamide 400 mg | 24 |
These were the proportions of patients losing 5% or more weight at 1-year relative to baseline. The measures were modeled with logistic regressions that included the three-level group proxy and a baseline weight covariate. (NCT00275834)
Timeframe: 1 year
| Intervention | participants (Number) |
|---|---|
| Placebo | 23 |
| Zonisamide 200 mg | 26 |
| Zonisamide 400 mg | 41 |
Hospital Anxiety and Depression Scale - Depression (HADS-D) The HADS is a 14-item self-administered questionnaire that consists of 2 scales, one measuring anxiety (HADS-A), and the other measuring depression (HADS-D). Each subscale consists of 7 statements and the participant responds as to how each item applies to him/her over the past week on 4-point response scale. Separate scores are calculated for anxiety and depression and a score (ranging from 0 to 21) is obtained for each subscale. The higher the score, the more severe the anxiety or depression. (NCT00275834)
Timeframe: 1 year
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Placebo | 2.12 |
| Zonisamide 200 mg | 2.76 |
| Zonisamide 400 mg | 1.95 |
Analyses was based on intent-to-treat ANCOVA. Difference scores from baseline to endpoint (Month-12) for each measure were regressed on the three-level proxy denoting group while controlling for the baseline value of the same measure. Contrasts were subsequently estimated in models, which had a significant overall treatment effect. (NCT00275834)
Timeframe: 1 year
| Intervention | cm (Mean) |
|---|---|
| Placebo | -4.8 |
| Zonisamide 200 mg | -6.1 |
| Zonisamide 400 mg | -8.5 |
(NCT00275834)
Timeframe: Baseline, 1 year
| Intervention | mm Hg (Least Squares Mean) | |
|---|---|---|
| Systolic | Diastolic | |
| Placebo | -0.6 | -1.5 |
| Zonisamide 200 mg | -4.4 | -3.6 |
| Zonisamide 400 mg | -1.9 | -3.9 |
(NCT00275834)
Timeframe: baseline, 1 year
| Intervention | mg/dL (Least Squares Mean) | |||
|---|---|---|---|---|
| Total Cholesterol | LDL Cholesterol | HDL Cholesterol | Triglycerides | |
| Placebo | -1.9 | -2.0 | 2.5 | -11.3 |
| Zonisamide 200 mg | 4.1 | 1.7 | 1.5 | 0.7 |
| Zonisamide 400 mg | -0.1 | -0.3 | 3.4 | -11.7 |
7 reviews available for zonisamide and Obesity
| Article | Year |
|---|---|
Antiobesity carbonic anhydrase inhibitors: a literature and patent review.
Topics: Animals; Anti-Obesity Agents; Carbonic Anhydrase Inhibitors; Carbonic Anhydrases; Drug Design; Fruct | 2013 |
Current and emerging medications for overweight or obesity in people with comorbidities.
Topics: Anti-Obesity Agents; Bupropion; Cinnamates; Comorbidity; Cyclohexanes; Diabetes Mellitus; Dyslipidem | 2015 |
[ZONISAMIDE: FIRST CHOICE AMONG THE FIRST-LINE ANTIEPILEPTIC DRUGS IN FOCAL EPILEPSY].
Topics: Adolescent; Age Factors; Aged; Aged, 80 and over; Anticonvulsants; Carbamazepine; Drug Administratio | 2015 |
Carbonic anhydrase inhibitors as emerging drugs for the treatment of obesity.
Topics: Anti-Obesity Agents; Carbonic Anhydrase Inhibitors; Cytosol; Fructose; Humans; Isoxazoles; Mitochond | 2008 |
[Role of zonisamid in treating epilepsy, Parkinson disorders and other neurological diseases].
Topics: Anticonvulsants; Bipolar Disorder; Calcium Channels, T-Type; Cholinergic Agents; Dopamine Agents; Dy | 2009 |
Pharmacologic treatment of obesity.
Topics: Anti-Obesity Agents; Appetite Depressants; Cyclobutanes; Fructose; Humans; Isoxazoles; Lactones; Obe | 2006 |
Emerging concepts in the medical and surgical treatment of obesity.
Topics: Adipose Tissue; Amyloid; Anticonvulsants; Antidepressive Agents; Anxiety; Appetite Regulation; Baria | 2008 |
6 trials available for zonisamide and Obesity
| Article | Year |
|---|---|
The effect of zonisamide on antipsychotic-associated weight gain in patients with schizophrenia: a randomized, double-blind, placebo-controlled clinical trial.
Topics: Adult; Antipsychotic Agents; Body Mass Index; Double-Blind Method; Female; Follow-Up Studies; Humans | 2013 |
Weight changes in obese adults 6-months after discontinuation of double-blind zonisamide or placebo treatment.
Topics: Adult; Anti-Obesity Agents; Anticonvulsants; Body Mass Index; Cohort Studies; Combined Modality Ther | 2014 |
Zonisamide for weight reduction in obese adults: a 1-year randomized controlled trial.
Topics: Adolescent; Adult; Aged; Antioxidants; Body Mass Index; Dose-Response Relationship, Drug; Double-Bli | 2012 |
Zonisamide for weight loss in obese adults: a randomized controlled trial.
Topics: Adult; Anti-Obesity Agents; Anticonvulsants; Body Mass Index; Caloric Restriction; Combined Modality | 2003 |
Zonisamide in the treatment of binge eating disorder with obesity: a randomized controlled trial.
Topics: Adult; Anticonvulsants; Body Mass Index; Bulimia; Dose-Response Relationship, Drug; Double-Blind Met | 2006 |
Combination therapy of zonisamide and bupropion for weight reduction in obese women: a preliminary, randomized, open-label study.
Topics: Adult; Analysis of Variance; Anti-Obesity Agents; Bupropion; Drug Therapy, Combination; Female; Huma | 2007 |
3 other studies available for zonisamide and Obesity
| Article | Year |
|---|---|
Low serum leptin level is associated with zonisamide-induced weight loss in overweight female epilepsy patients.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Epilepsy; Female; Follow-Up Studies; Humans; Isoxazoles; L | 2012 |
Zonisamide: no magic bullet.
Topics: Female; Humans; Isoxazoles; Male; Obesity; Weight Loss; Zonisamide | 2012 |
Zonisamide prevents olanzapine-associated hyperphagia, weight gain, and elevated blood glucose in rats.
Topics: Animals; Anticonvulsants; Appetite Regulation; Benzodiazepines; Biomarkers; Body Weight; Diabetes Me | 2008 |